X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2068) 2068
Publication (260) 260
Book Review (48) 48
Book Chapter (9) 9
Conference Proceeding (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pegylated liposomal doxorubicin (1786) 1786
humans (1433) 1433
index medicus (1241) 1241
oncology (1031) 1031
female (846) 846
chemotherapy (709) 709
cancer (579) 579
pharmacology & pharmacy (446) 446
middle aged (440) 440
ovarian cancer (440) 440
aged (413) 413
ovarian neoplasms - drug therapy (379) 379
antineoplastic combined chemotherapy protocols - therapeutic use (370) 370
animals (347) 347
antineoplastic agents - therapeutic use (346) 346
adult (339) 339
doxorubicin - administration & dosage (338) 338
treatment outcome (300) 300
anthracyclines (295) 295
doxorubicin - analogs & derivatives (283) 283
paclitaxel (270) 270
care and treatment (260) 260
doxorubicin (252) 252
pegylated-liposomal doxorubicin (233) 233
nanoparticles (232) 232
drug delivery systems (230) 230
phase-ii trial (229) 229
male (222) 222
carcinoma (205) 205
trial (204) 204
therapy (203) 203
doxorubicin - adverse effects (200) 200
neoplasms - drug therapy (195) 195
polyethylene glycols - administration & dosage (191) 191
research (190) 190
doxorubicin - therapeutic use (189) 189
obstetrics & gynecology (185) 185
antineoplastic agents - administration & dosage (182) 182
liposomes (178) 178
phase-iii trial (176) 176
drug therapy (175) 175
hematology, oncology and palliative medicine (173) 173
phase-ii (172) 172
disease-free survival (170) 170
antineoplastic combined chemotherapy protocols - adverse effects (168) 168
hematology (167) 167
breast cancer (163) 163
neoplasm recurrence, local - drug therapy (161) 161
ovarian neoplasms - pathology (160) 160
aged, 80 and over (156) 156
toxicity (155) 155
drugs (154) 154
pharmacokinetics (153) 153
breast neoplasms - drug therapy (152) 152
antineoplastic agents - adverse effects (151) 151
drug resistance, neoplasm (150) 150
health aspects (149) 149
randomized phase-iii (148) 148
article (146) 146
analysis (142) 142
medicine & public health (139) 139
polyethylene glycols - adverse effects (139) 139
carboplatin (136) 136
tumors (136) 136
bortezomib (135) 135
multiple myeloma (135) 135
solid tumors (133) 133
breast-cancer (131) 131
drug-delivery (130) 130
mice (127) 127
metastatic breast-cancer (126) 126
chemistry, multidisciplinary (124) 124
gynecologic-oncology-group (124) 124
multiple myeloma - drug therapy (122) 122
cell line, tumor (117) 117
cisplatin (117) 117
clinical trials (117) 117
drug delivery (114) 114
in-vivo (112) 112
vehicles (112) 112
antitumor-activity (111) 111
cardiotoxicity (111) 111
gemcitabine (110) 110
antineoplastic agents - pharmacology (109) 109
combination (109) 109
nanoscience & nanotechnology (107) 107
neoplasm staging (107) 107
antibiotics, antineoplastic - administration & dosage (106) 106
nanotechnology (105) 105
stem-cell transplantation (104) 104
polyethylene glycols - therapeutic use (103) 103
topotecan (103) 103
drug administration schedule (102) 102
cancer therapies (100) 100
nanomedicine (100) 100
retrospective studies (100) 100
prognosis (95) 95
bevacizumab (93) 93
clinical trials as topic (93) 93
breast neoplasms - pathology (92) 92
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2022) 2022
French (16) 16
German (13) 13
Polish (11) 11
Spanish (8) 8
Japanese (3) 3
Russian (3) 3
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2006, Volume 106, Issue 4, pp. 848 - 858
BACKGROUND. Pegylated liposomal doxorubicin has pharmacologic and safety advantages over conventional doxorubicin. METHODS. For this noninteriority trial, 192... 
Dexamethasone | Neutropenic fever | Drug toxicity | Multiple myeloma | Liposomes | Drug resistance | Doxorubicin | Pegylated liposomal doxorubicin | Vincristine | Neoplasms | dexamethasone | 1ST-LINE TREATMENT | multiple myeloma | vincristine | ONCOLOGY-GROUP | liposomes | COMBINATION THERAPY | neutropenic fever | CONVENTIONAL DOXORUBICIN | TRANSPLANTATION | pegylated liposomal doxorubicin | THALIDOMIDE PLUS DEXAMETHASONE | KAPOSIS-SARCOMA | ONCOLOGY | drug toxicity | REDUCED-DOSE DEXAMETHASONE | VAD | doxorubicin | drug resistance | neoplasms | DVD-T | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Fever - chemically induced | Multiple Myeloma - drug therapy | Doxorubicin - analogs & derivatives | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Administration, Oral | Catheterization, Central Venous | Treatment Outcome | Polyethylene Glycols - administration & dosage | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Infusions, Intravenous | Doxorubicin - adverse effects | Pharmaceutical research | Drugs | Myelocytic leukemia | Reports | Nonlymphoid leukemia | Research | Drug therapy, Combination | Drug therapy | Health aspects
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 04/2017, Volume 31, Issue 4, pp. np - n/a
Journal Article
Drugs, ISSN 0012-6667, 2011, Volume 71, Issue 18, pp. 2531 - 2558
Journal Article
Nuclear Medicine and Biology, ISSN 0969-8051, 2009, Volume 36, Issue 5, pp. 515 - 524
Journal Article
Nanomedicine, ISSN 1743-5889, 10/2015, Volume 10, Issue 19, pp. 2963 - 2971
Aim: To test the efficacy and toxicity of exosomal doxorubicin (exoDOX) compared with free doxorubicin. Materials & methods: The cytotoxic effects of exoDOX... 
toxicity | breast cancer | nanomedicine | exosomal doxorubicin | drug delivery | exosome | NANOPARTICLE TRACKING ANALYSIS | PEGYLATED LIPOSOMAL DOXORUBICIN | DENDRITIC CELLS | CANCER CELLS | VESICLES | CARDIOTOXICITY | NANOSCIENCE & NANOTECHNOLOGY | MICRORNAS | MEDIATED TRANSFER | DELIVERY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | MICE
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2015, Volume 210, pp. 198 - 207
Combinations of topoisomerase inhibitors I and II have been found to synergistically inhibit cancer cell growth in vitro, yet clinical studies of these types... 
Synergistic | Chemotherapy | Drug combinations | Polymer drug conjugate | SINGLE-AGENT CHEMOTHERAPY | CHEMISTRY, MULTIDISCIPLINARY | OVARIAN-CARCINOMA | CELL LUNG-CANCER | HUMAN BREAST-CARCINOMA | ZOLEDRONIC ACID | PHASE-I TRIAL | ENDOTHELIAL-CELLS | IRINOTECAN | PHARMACOLOGY & PHARMACY | PEGYLATED-LIPOSOMAL DOXORUBICIN | CYTOTOXIC AGENTS | Hyaluronic Acid - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Camptothecin - chemistry | Apoptosis - drug effects | Humans | Hyaluronic Acid - chemistry | Topoisomerase I Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - chemistry | Topoisomerase II Inhibitors - administration & dosage | Doxorubicin - chemistry | Neoplasms - drug therapy | Drug Synergism | Antineoplastic Agents, Phytogenic - administration & dosage | Animals | Topoisomerase II Inhibitors - chemistry | Tumor Burden - drug effects | Cell Line, Tumor | Camptothecin - administration & dosage | Female | Mice, Inbred BALB C | Neoplasms - pathology | Topoisomerase I Inhibitors - chemistry | Doxorubicin - administration & dosage | Hyaluronic acid | Anthracyclines | Analysis | Medical research | Medicine, Experimental | Drug therapy, Combination | Polymers | Index Medicus | synergistic | polymer drug conjugate | chemotherapy | drug combinations
Journal Article
Journal Article
Journal Article
Life Sciences, ISSN 0024-3205, 05/2018, Volume 200, pp. 26 - 30
Doxorubicin (Dox) is a valuable anticancer drug for hematologic and solid tumors. Yet, it can cause multi-organ toxicities in various patients. Since toxicity... 
Oxidative stress | Toxicity | Doxorubicin | Multi-organ | Mechanism | MEDICINE, RESEARCH & EXPERIMENTAL | PEGYLATED LIPOSOMAL DOXORUBICIN | CELLS | RATS | MEDIATED APOPTOSIS | OVARIAN-CANCER | NANOPARTICLES | INDUCED CARDIOTOXICITY | IN-VITRO | RADIATION RECALL | PHARMACOLOGY & PHARMACY | Medicine, Experimental | Medical colleges | Medical research | Anthracyclines | Green products | Index Medicus
Journal Article
Journal Article